ArticleScientific reports2026
M2 type macrophages promote OSCC progress via conferring resistance to Erastin-induced ferroptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron homeostasis and macrophage polarization in oral squamous cell carcinoma: mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionM2 type macrophages could promote oral squamous cell carcinoma (OSCC) progress. Ferroptosis is a newly discovered type of programmed cell death and inhibition of ferroptosis in many tumor models could promote tumor progression. This study aims to investigate whether M2 type macrophages could influence the progression of OSCC by regulating the ferroptosis of tumor cells.
methodsImmunohistochemical staining was performed to verify the correlation between the expression of CD206 representing M2 type macrophage infiltration in tumor tissue, and GPX4 representing the ability to resist ferroptosis in vivo. In vitro, treat OSCC cells with ferroptosis inducers at different concentrations, detect their effects on ferroptosis, and meanwhile observe their impacts on the proliferation, migration and invasion abilities of OSCC cells; stimulate macrophages to generate different polarization states and identify them. Then, OSCC cells with different levels of ferroptosis were treated with products from macrophages of different polarized states, and the effects on ferroptosis and proliferation, migration and invasion ability of OSCC cells were observed and detected.
resultsCD206 and GPX4 expression in OSCC clinical samples were positively correlated. With the downregulation of ferroptosis, the proliferation, migration and invasion of OSCC cells were inhibited, and M2 type macrophages can upregulate ferroptosis of OSCC cells, meanwhile enhancing their proliferation, migration and invasion capacity.
conclusionsOur studies demonstrated M2 type macrophages could accelerate the progression of OSCC by augmenting the capacity of OSCC cells to resist ferroptosis. CLINICAL SIGNIFICANCE: Our studies might offer insights for the application of ferroptosis or macrophage polarization in the therapy of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.